구강붕해정(ODT) 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2025-2032년)

Orally Disintegrating Tablet Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

US $ 4,995 ￦ 6,828,000

Unprintable PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 복사, 인쇄가 불가능합니다.

US $ 7,295 ￦ 9,972,000

PDF & Excel (Multi User License)

PDF, Excel 보고서를 동일 기업 내 5명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

US $ 8,495 ￦ 11,613,000

PDF & Excel (Corporate User License)

PDF, Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

한글목차

주요 조사 결과

• 구강붕해정(ODT) 시장 규모 : 250억 8,210만 달러(2025년 기준)
• 예상 시장 규모 : 481억 8,680만 달러(2032년)
• 세계 시장 성장률 : 8.5%(2025-2032년 CAGR)

구강붕해정(ODT) 시장 - 보고서 범위

구강붕해정(ODT) 시장은 물 없이도 구강 내에서 빠르게 용해되거나 분해되는 약물로 구성됩니다. 이러한 정제는 복용이 용이하고, 환자 순응도가 높으며, 소아 및 노약자에게 적합하기 때문에 다양한 치료 영역에서 널리 사용되고 있습니다. 혁신적인 약물전달 시스템에 대한 수요 증가와 만성질환 및 신경 질환의 유병률 증가로 인해 ODT의 채택이 가속화되고 있습니다. 제약사들은 환자의 미충족 수요를 겨냥한 첨단 제형 기술에 투자하여 포트폴리오를 확장하고 시장 점유율을 확대하고 있습니다.

시장 성장 촉진요인

세계 ODT 시장은 여러 가지 유리한 요인으로 인해 꾸준한 성장세를 보이고 있습니다. 간질, 파킨슨병, 정신분열증과 같은 신경 및 정신질환의 유병률 증가는 ODT가 삼키기 어려운 환자들에게 편리한 제형이라는 점에서 수요에 크게 기여하고 있습니다. 또한, 기존 정제 복용이 어려운 두 가지 중요한 계층인 소아 및 노인층의 확대는 ODT의 채택을 더욱 촉진하고 있습니다. 또한, 진통 및 알레르기 등의 치료 영역에서 빠른 효과를 보이는 제제에 대한 수요가 증가함에 따라 제약사들이 기존 약물의 ODT 버전을 개발하는 데 박차를 가하고 있습니다. 미각 마스킹과 빠른 분해의 기술적 진보도 환자의 복약 순응도와 치료 결과를 개선하기 위해 더 맛있고 효과적인 ODT의 개발을 촉진하고 있습니다.

시장 억제요인

ODT 시장은 강력한 성장이 예상되는 반면, 여러 가지 제약에 직면해 있습니다. 주요 과제 중 하나는 기존 정제 대비 ODT의 제조가 복잡하고 비용이 많이 든다는 점입니다. 이러한 제제는 동결건조나 직접 타정 등 특수한 장비와 기술을 필요로 하는 경우가 많아 자본 집약적일 수 있습니다. 또한, 모든 의약품이 ODT 제형에 적합한 것은 아니며, 특히 필요한 용량이 많은 의약품이나 효과적인 마스킹이 어려운 불쾌한 맛을 가진 의약품에는 적합하지 않습니다. 특히 습기에 민감한 화합물의 경우, 규제상의 장애물이나 안정성 문제로 인해 제품 승인 및 시장 출시 시간이 지연되어 성장을 저해할 수 있습니다.

시장 기회

ODT 시장에는 성장과 혁신의 기회가 많습니다. 환자 중심의 약물 설계에 대한 관심이 높아지고 자가투여 약물의 인기가 높아짐에 따라 시장 확대를 위한 강력한 기반이 되고 있습니다. 제약사들은 제품 차별화와 특허 기간 연장을 위해 ODT에 적합한 새로운 API와 다제 복합제를 찾고 있습니다. 아시아태평양, 라틴아메리카, 중동 및 아프리카의 신흥 시장에서 의료 접근성 확대, 특히 온라인 및 소매 약국 채널을 통한 미개발 잠재력이 있습니다. 또한, 제약회사와 위탁생산(CMO)의 전략적 제휴를 통해 비용 효율적인 생산이 가능해져 새로운 ODT 제품의 신속한 상용화가 가능해질 것입니다.

이 보고서는 세계 구강붕해정(ODT) 시장에 대해 조사했으며, 성장 촉진요인, 동향, 기회, 과제 등 시장 역학에 대한 상세한 분석을 제공합니다.

목차

제1장 주요 요약

제2장 시장 개요

• 시장 범위와 정의
• 시장 역학
  • 성장 촉진요인
  • 성장 억제요인
  • 기회
  • 과제
  • 주요 동향
• 거시경제 요인
  • 세계의 부문 전망
  • 세계의 GDP 성장 전망
• COVID-19의 영향 분석
• 예측요인 - 관련성과 영향

제3장 부가가치 인사이트

• 규제 상황
• 제품 채용 분석
• 밸류체인 분석
• 주요 거래와 합병
• PESTLE 분석
• Porter's Five Forces 분석

제4장 세계의 구강붕해정(ODT) 시장 전망

• 주요 하이라이트
  • 시장 규모와 전년비 성장
  • 절대적 수익 기회
• 시장 규모 분석과 예측
  • 시장 규모 실적 분석(2019-2024년)
  • 현재 시장 규모 분석과 예측(2025-2032년)
• 세계의 구강붕해정(ODT) 시장 전망 : 약물 종류
  • 소개/주요 조사 결과
  • 시장 규모 실적 분석 : 약물 종류별(2019-2024년)
  • 현재 시장 규모 분석과 예측 : 약물 종류별(2025-2032년)
  • 시장 매력 분석 : 약물 종류
• 세계의 구강붕해정(ODT) 시장 전망 : 적응증
  • 소개/주요 조사 결과
  • 시장 규모 실적 분석 : 적응증별(2019-2024년)
  • 현재 시장 규모 분석과 예측 : 적응증별(2025-2032년)
  • 시장 매력 분석 : 적응증
• 세계의 구강붕해정(ODT) 시장 전망 : 유통 채널
  • 소개/주요 조사 결과
  • 시장 규모 실적 분석 : 유통 채널별(2019-2024년)
  • 현재 시장 규모 분석과 예측 : 유통 채널별(2025-2032년)
  • 시장 매력 분석 : 유통 채널

제5장 세계의 구강붕해정(ODT) 시장 전망 : 지역

• 주요 하이라이트
• 시장 규모 실적 분석 : 지역별(2019-2024년)
• 현재 시장 규모 분석과 예측 : 지역별(2025-2032년)
  • 북미
  • 유럽
  • 동아시아
  • 남아시아 및 오세아니아
  • 라틴아메리카
  • 중동 및 아프리카
• 시장 매력 분석 : 지역

제6장 북미의 구강붕해정(ODT) 시장 전망

제7장 유럽의 구강붕해정(ODT) 시장 전망

제8장 동아시아의 구강붕해정(ODT) 시장 전망

제9장 남아시아 및 오세아니아의 구강붕해정(ODT) 시장 전망

제10장 라틴아메리카의 구강붕해정(ODT) 시장 전망

제11장 중동 및 아프리카의 구강붕해정(ODT) 시장 전망

제12장 경쟁 구도

• 시장 점유율 분석(2025년)
• 시장 구조
  • 경쟁 강도 맵 : 시장별
  • 경쟁 대시보드
• 기업 개요(상세 - 개요, 재무, 전략, 최근 발전)
  • Teva Pharmaceutical Industries Ltd.
  • Novartis AG
  • AstraZeneca
  • Mylan NV
  • Pfizer Inc.
  • Johnson & Johnson Services, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
  • Bausch Health
  • GlaxoSmithKline plc.
  • Sun Pharmaceutical Industries Ltd.
  • Bayer AG
  • Eli Lily and Company
  • Dr. Reddy's Laboratories Ltd.
  • Takeda Pharmaceutical Company Limited
  • Catalent Pharma Solutions
  • Neos Therapeutics
  • Eisai Co.
  • Zydus Lifesciences
  • Aurobindo Pharma
  • Torrent Pharmaceuticals

제13장 부록

ksm

영문 목차

영문목차

Persistence Market Research has recently released a comprehensive report on the global Orally Disintegrating Tablet (ODT) Market, providing an in-depth analysis of key market dynamics, including driving forces, emerging trends, opportunities, and challenges. This report offers a detailed understanding of the market landscape, helping stakeholders make well-informed decisions.

Key Insights:

• Orally Disintegrating Tablet Market Size (2025E): US$ 25,082.1 Mn
• Projected Market Value (2032F): US$ 48,186.8 Mn
• Global Market Growth Rate (CAGR 2025 to 2032): 8.5%

Orally Disintegrating Tablet Market - Report Scope:

The Orally Disintegrating Tablet (ODT) market comprises pharmaceutical formulations that dissolve or disintegrate rapidly in the mouth without the need for water. These tablets are widely used across various therapeutic areas due to their ease of administration, improved patient compliance, and suitability for pediatric and geriatric populations. Rising demand for innovative drug delivery systems, coupled with growing prevalence of chronic and neurological disorders, is accelerating the adoption of ODTs. Pharmaceutical companies are investing in advanced formulation technologies and targeting unmet patient needs to expand their portfolios and capture greater market share.

Market Growth Drivers:

The global ODT market is experiencing steady growth due to several favorable factors. The increasing incidence of neurological and psychiatric conditions, such as epilepsy, Parkinson's disease, and schizophrenia, is contributing significantly to demand, as ODTs offer a more convenient dosage form for patients who have difficulty swallowing. Moreover, the growing pediatric and geriatric population-two key demographics for whom traditional tablets pose challenges-further drives the adoption of ODTs. Additionally, the rise in demand for faster-acting formulations in therapeutic areas like pain relief and allergies has encouraged pharmaceutical firms to develop ODT versions of existing drugs. Technological advancements in taste-masking and rapid disintegration are also facilitating the development of more palatable and effective ODTs, enhancing patient adherence and therapeutic outcomes.

Market Restraints:

Despite strong growth prospects, the ODT market faces several limitations. One of the key challenges is the complexity and cost of manufacturing ODTs compared to conventional tablets. These formulations often require specialized equipment and technologies such as lyophilization or direct compression, which can be capital-intensive. Moreover, not all drugs are suitable for ODT formulations, especially those with high dosage requirements or unpleasant taste profiles that are difficult to mask effectively. Regulatory hurdles and stability concerns, particularly with moisture-sensitive compounds, can also delay product approvals and time-to-market, thereby restraining growth.

Market Opportunities:

The ODT market presents numerous opportunities for growth and innovation. Increasing focus on patient-centric drug design and the growing popularity of self-administered medication provide a strong foundation for market expansion. Pharmaceutical companies are exploring novel APIs and fixed-dose combinations suitable for ODTs to differentiate their product offerings and extend patent life. Expanding access to healthcare in emerging markets across Asia-Pacific, Latin America, and the Middle East and Africa presents untapped potential, particularly through online and retail pharmacy channels. Furthermore, strategic collaborations between drug developers and contract manufacturing organizations (CMOs) can facilitate cost-effective production and faster commercialization of new ODT products.

Key Questions Answered in the Report:

• What are the primary factors driving the global ODT market's growth?
• Which regions and therapeutic segments are witnessing the highest demand for ODTs?
• How are innovations in formulation technology influencing market dynamics?
• Who are the key players in the ODT market, and what strategies are they adopting to remain competitive?
• What are the emerging trends and future projections for the global ODT market?

Competitive Intelligence and Business Strategy:

Leading companies in the global ODT market, such as Teva Pharmaceutical Industries Ltd., Novartis AG, AstraZeneca, Mylan N.V., and Pfizer Inc., are focusing on formulation innovation, lifecycle management of blockbuster drugs, and expanding their presence in high-growth regions. These players are also investing in taste-masking technologies, disintegration enhancers, and fast-melt systems to improve patient experience and treatment outcomes. Strategic partnerships, mergers and acquisitions, and co-development agreements are common approaches to gain competitive advantage. In addition, the emergence of digital pharmacies and evolving consumer preferences toward convenience-based healthcare solutions are shaping new business models in the ODT landscape.

Companies Covered in This Report:

• Teva Pharmaceutical Industries Ltd.
• Novartis AG
• AstraZeneca
• Mylan N.V.
• Pfizer Inc.
• Johnson & Johnson Services, Inc.
• F. Hoffmann-La Roche Ltd.
• Merck & Co., Inc.
• Bausch Health
• GlaxoSmithKline plc.
• Sun Pharmaceutical Industries Ltd.
• Bayer AG
• Eli Lilly and Company

Orally Disintegrating Tablet Market Segmentation:

By Drug Class:

• Anti-Psychotics
• Anti-Epileptics
• CNS Stimulants
• Anxiolytics
• Anti-Parkinsonian Drugs
• Anti-Hypertensives
• NSAIDs
• Anti-Allergy Drugs
• Proton Pump Inhibitors
• Others

By Disease Indication:

• CNS Diseases
• GI Diseases
• CVS Disorders
• Allergy
• Others

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Drug Stores
• Online Pharmacies

By Region:

• North America
• Europe
• East Asia
• South Asia and Oceania
• Latin America
• Middle East and Africa

Table of Contents

1. Executive Summary

• 1.1. Global Orally Disintegrating Tablet Market Snapshot, 2025-2032
• 1.2. Market Opportunity Assessment, 2025-2032, US$ Mn
• 1.3. Key Market Trends
• 1.4. Future Market Projections
• 1.5. Premium Market Insights
• 1.6. Industry Developments and Key Market Events
• 1.7. PMR Analysis and Recommendations

2. Market Overview

• 2.1. Market Scope and Definition
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Opportunity
  • 2.2.4. Challenges
  • 2.2.5. Key Trends
• 2.3. Macro-Economic Factors
  • 2.3.1. Global Sectorial Outlook
  • 2.3.2. Global GDP Growth Outlook
• 2.4. COVID-19 Impact Analysis
• 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

• 3.1. Regulatory Landscape
• 3.2. Product Adoption Analysis
• 3.3. Value Chain Analysis
• 3.4. Key Deals and Mergers
• 3.5. PESTLE Analysis
• 3.6. Porter's Five Force Analysis

4. Global Orally Disintegrating Tablet Market Outlook:

• 4.1. Key Highlights
  • 4.1.1. Market Size (US$ Mn) and Y-o-Y Growth
  • 4.1.2. Absolute $ Opportunity
• 4.2. Market Size (US$ Mn) Analysis and Forecast
  • 4.2.1. Historical Market Size (US$ Mn) Analysis, 2019-2024
  • 4.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2025-2032
• 4.3. Global Orally Disintegrating Tablet Market Outlook: Drug Class
  • 4.3.1. Introduction / Key Findings
  • 4.3.2. Historical Market Size (US$ Mn) Analysis, By Drug Class, 2019-2024
  • 4.3.3. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2025-2032
    • 4.3.3.1. Anti-Psychotics
    • 4.3.3.2. Anti-Epileptics
    • 4.3.3.3. CNS Stimulants
    • 4.3.3.4. Anxiolytics
    • 4.3.3.5. Anti-Parkinsonian Drugs
    • 4.3.3.6. Anti-Hypertensives
    • 4.3.3.7. NSAIDS
    • 4.3.3.8. Anti-Allergy Drugs
    • 4.3.3.9. Proton Pump Inhibitors
    • 4.3.3.10. Others
  • 4.3.4. Market Attractiveness Analysis: Drug Class
• 4.4. Global Orally Disintegrating Tablet Market Outlook: Disease Indication
  • 4.4.1. Introduction / Key Findings
  • 4.4.2. Historical Market Size (US$ Mn) Analysis, By Disease Indication, 2019-2024
  • 4.4.3. Current Market Size (US$ Mn) Analysis and Forecast, By Disease Indication, 2025-2032
    • 4.4.3.1. CNS Diseases
    • 4.4.3.2. GI Diseases
    • 4.4.3.3. CVS Disorders
    • 4.4.3.4. Allergy
    • 4.4.3.5. Others
  • 4.4.4. Market Attractiveness Analysis: Disease Indication
• 4.5. Global Orally Disintegrating Tablet Market Outlook: Distribution Channel
  • 4.5.1. Introduction / Key Findings
  • 4.5.2. Historical Market Size (US$ Mn) Analysis, By Distribution Channel, 2019-2024
  • 4.5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
    • 4.5.3.1. Hospital Pharmacies
    • 4.5.3.2. Retail Pharmacies
    • 4.5.3.3. Drug Stores
    • 4.5.3.4. Online Pharmacies
  • 4.5.4. Market Attractiveness Analysis: Distribution Channel

5. Global Orally Disintegrating Tablet Market Outlook: Region

• 5.1. Key Highlights
• 5.2. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2024
• 5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2025-2032
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. East Asia
  • 5.3.4. South Asia and Oceania
  • 5.3.5. Latin America
  • 5.3.6. Middle East & Africa
• 5.4. Market Attractiveness Analysis: Region

6. North America Orally Disintegrating Tablet Market Outlook:

• 6.1. Key Highlights
• 6.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 6.2.1. By Country
  • 6.2.2. By Drug Class
  • 6.2.3. By Disease Indication
  • 6.2.4. By Distribution Channel
• 6.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 6.3.1. U.S.
  • 6.3.2. Canada
• 6.4. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2025-2032
  • 6.4.1. Anti-Psychotics
  • 6.4.2. Anti-Epileptics
  • 6.4.3. CNS Stimulants
  • 6.4.4. Anxiolytics
  • 6.4.5. Anti-Parkinsonian Drugs
  • 6.4.6. Anti-Hypertensives
  • 6.4.7. NSAIDS
  • 6.4.8. Anti-Allergy Drugs
  • 6.4.9. Proton Pump Inhibitors
  • 6.4.10. Others
• 6.5. Current Market Size (US$ Mn) Analysis and Forecast, By Disease Indication, 2025-2032
  • 6.5.1. CNS Diseases
  • 6.5.2. GI Diseases
  • 6.5.3. CVS Disorders
  • 6.5.4. Allergy
  • 6.5.5. Others
• 6.6. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
  • 6.6.1. Hospital Pharmacies
  • 6.6.2. Retail Pharmacies
  • 6.6.3. Drug Stores
  • 6.6.4. Online Pharmacies
• 6.7. Market Attractiveness Analysis

7. Europe Orally Disintegrating Tablet Market Outlook:

• 7.1. Key Highlights
• 7.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 7.2.1. By Country
  • 7.2.2. By Drug Class
  • 7.2.3. By Disease Indication
  • 7.2.4. By Distribution Channel
• 7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 7.3.1. Germany
  • 7.3.2. France
  • 7.3.3. U.K.
  • 7.3.4. Italy
  • 7.3.5. Spain
  • 7.3.6. Russia
  • 7.3.7. Turkey
  • 7.3.8. Rest of Europe
• 7.4. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2025-2032
  • 7.4.1. Anti-Psychotics
  • 7.4.2. Anti-Epileptics
  • 7.4.3. CNS Stimulants
  • 7.4.4. Anxiolytics
  • 7.4.5. Anti-Parkinsonian Drugs
  • 7.4.6. Anti-Hypertensives
  • 7.4.7. NSAIDS
  • 7.4.8. Anti-Allergy Drugs
  • 7.4.9. Proton Pump Inhibitors
  • 7.4.10. Others
• 7.5. Current Market Size (US$ Mn) Analysis and Forecast, By Disease Indication, 2025-2032
  • 7.5.1. CNS Diseases
  • 7.5.2. GI Diseases
  • 7.5.3. CVS Disorders
  • 7.5.4. Allergy
  • 7.5.5. Others
• 7.6. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
  • 7.6.1. Hospital Pharmacies
  • 7.6.2. Retail Pharmacies
  • 7.6.3. Drug Stores
  • 7.6.4. Online Pharmacies
• 7.7. Market Attractiveness Analysis

8. East Asia Orally Disintegrating Tablet Market Outlook:

• 8.1. Key Highlights
• 8.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 8.2.1. By Country
  • 8.2.2. By Drug Class
  • 8.2.3. By Disease Indication
  • 8.2.4. By Distribution Channel
• 8.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 8.3.1. China
  • 8.3.2. Japan
  • 8.3.3. South Korea
• 8.4. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2025-2032
  • 8.4.1. Anti-Psychotics
  • 8.4.2. Anti-Epileptics
  • 8.4.3. CNS Stimulants
  • 8.4.4. Anxiolytics
  • 8.4.5. Anti-Parkinsonian Drugs
  • 8.4.6. Anti-Hypertensives
  • 8.4.7. NSAIDS
  • 8.4.8. Anti-Allergy Drugs
  • 8.4.9. Proton Pump Inhibitors
  • 8.4.10. Others
• 8.5. Current Market Size (US$ Mn) Analysis and Forecast, By Disease Indication, 2025-2032
  • 8.5.1. CNS Diseases
  • 8.5.2. GI Diseases
  • 8.5.3. CVS Disorders
  • 8.5.4. Allergy
  • 8.5.5. Others
• 8.6. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
  • 8.6.1. Hospital Pharmacies
  • 8.6.2. Retail Pharmacies
  • 8.6.3. Drug Stores
  • 8.6.4. Online Pharmacies
• 8.7. Market Attractiveness Analysis

9. South Asia & Oceania Orally Disintegrating Tablet Market Outlook:

• 9.1. Key Highlights
• 9.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 9.2.1. By Country
  • 9.2.2. By Drug Class
  • 9.2.3. By Disease Indication
  • 9.2.4. By Distribution Channel
• 9.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 9.3.1. India
  • 9.3.2. Southeast Asia
  • 9.3.3. ANZ
  • 9.3.4. Rest of South Asia & Oceania
• 9.4. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2025-2032
  • 9.4.1. Anti-Psychotics
  • 9.4.2. Anti-Epileptics
  • 9.4.3. CNS Stimulants
  • 9.4.4. Anxiolytics
  • 9.4.5. Anti-Parkinsonian Drugs
  • 9.4.6. Anti-Hypertensives
  • 9.4.7. NSAIDS
  • 9.4.8. Anti-Allergy Drugs
  • 9.4.9. Proton Pump Inhibitors
  • 9.4.10. Others
• 9.5. Current Market Size (US$ Mn) Analysis and Forecast, By Disease Indication, 2025-2032
  • 9.5.1. CNS Diseases
  • 9.5.2. GI Diseases
  • 9.5.3. CVS Disorders
  • 9.5.4. Allergy
  • 9.5.5. Others
• 9.6. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
  • 9.6.1. Hospital Pharmacies
  • 9.6.2. Retail Pharmacies
  • 9.6.3. Drug Stores
  • 9.6.4. Online Pharmacies
• 9.7. Market Attractiveness Analysis

10. Latin America Orally Disintegrating Tablet Market Outlook:

• 10.1. Key Highlights
• 10.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 10.2.1. By Country
  • 10.2.2. By Drug Class
  • 10.2.3. By Disease Indication
  • 10.2.4. By Distribution Channel
• 10.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 10.3.1. Brazil
  • 10.3.2. Mexico
  • 10.3.3. Rest of Latin America
• 10.4. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2025-2032
  • 10.4.1. Anti-Psychotics
  • 10.4.2. Anti-Epileptics
  • 10.4.3. CNS Stimulants
  • 10.4.4. Anxiolytics
  • 10.4.5. Anti-Parkinsonian Drugs
  • 10.4.6. Anti-Hypertensives
  • 10.4.7. NSAIDS
  • 10.4.8. Anti-Allergy Drugs
  • 10.4.9. Proton Pump Inhibitors
  • 10.4.10. Others
• 10.5. Current Market Size (US$ Mn) Analysis and Forecast, By Disease Indication, 2025-2032
  • 10.5.1. CNS Diseases
  • 10.5.2. GI Diseases
  • 10.5.3. CVS Disorders
  • 10.5.4. Allergy
  • 10.5.5. Others
• 10.6. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
  • 10.6.1. Hospital Pharmacies
  • 10.6.2. Retail Pharmacies
  • 10.6.3. Drug Stores
  • 10.6.4. Online Pharmacies
• 10.7. Market Attractiveness Analysis

11. Middle East & Africa Orally Disintegrating Tablet Market Outlook:

• 11.1. Key Highlights
• 11.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 11.2.1. By Country
  • 11.2.2. By Drug Class
  • 11.2.3. By Disease Indication
  • 11.2.4. By Distribution Channel
• 11.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 11.3.1. GCC Countries
  • 11.3.2. Egypt
  • 11.3.3. South Africa
  • 11.3.4. Northern Africa
  • 11.3.5. Rest of Middle East & Africa
• 11.4. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2025-2032
  • 11.4.1. Anti-Psychotics
  • 11.4.2. Anti-Epileptics
  • 11.4.3. CNS Stimulants
  • 11.4.4. Anxiolytics
  • 11.4.5. Anti-Parkinsonian Drugs
  • 11.4.6. Anti-Hypertensives
  • 11.4.7. NSAIDS
  • 11.4.8. Anti-Allergy Drugs
  • 11.4.9. Proton Pump Inhibitors
  • 11.4.10. Others
• 11.5. Current Market Size (US$ Mn) Analysis and Forecast, By Disease Indication, 2025-2032
  • 11.5.1. CNS Diseases
  • 11.5.2. GI Diseases
  • 11.5.3. CVS Disorders
  • 11.5.4. Allergy
  • 11.5.5. Others
• 11.6. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
  • 11.6.1. Hospital Pharmacies
  • 11.6.2. Retail Pharmacies
  • 11.6.3. Drug Stores
  • 11.6.4. Online Pharmacies
• 11.7. Market Attractiveness Analysis

12. Competition Landscape

• 12.1. Market Share Analysis, 2025
• 12.2. Market Structure
  • 12.2.1. Competition Intensity Mapping By Market
  • 12.2.2. Competition Dashboard
• 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  • 12.3.1. Teva Pharmaceutical Industries Ltd.
    • 12.3.1.1. Overview
    • 12.3.1.2. Segments and Products
    • 12.3.1.3. Key Financials
    • 12.3.1.4. Market Developments
    • 12.3.1.5. Market Strategy
  • 12.3.2. Novartis AG
  • 12.3.3. AstraZeneca
  • 12.3.4. Mylan N.V.
  • 12.3.5. Pfizer Inc.
  • 12.3.6. Johnson & Johnson Services, Inc.
  • 12.3.7. F. Hoffmann-La Roche Ltd.
  • 12.3.8. Merck & Co., Inc.
  • 12.3.9. Bausch Health
  • 12.3.10. GlaxoSmithKline plc.
  • 12.3.11. Sun Pharmaceutical Industries Ltd.
  • 12.3.12. Bayer AG
  • 12.3.13. Eli Lily and Company
  • 12.3.14. Dr. Reddy's Laboratories Ltd.
  • 12.3.15. Takeda Pharmaceutical Company Limited
  • 12.3.16. Catalent Pharma Solutions
  • 12.3.17. Neos Therapeutics
  • 12.3.18. Eisai Co.
  • 12.3.19. Zydus Lifesciences
  • 12.3.20. Aurobindo Pharma
  • 12.3.21. Torrent Pharmaceuticals

13. Appendix

• 13.1. Research Methodology
• 13.2. Research Assumptions
• 13.3. Acronyms and Abbreviations

관련자료